Drugs / ALN-4915
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07535606 | Mar 2026 → Jul 2027 expected | — | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-4915 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07535606 ↗ |
| Route | Subcutaneous | “ALN-4915 will be administered subcutaneously (SC)” NCT07535606 ↗ |